Search research articles
Contact Us
Filters
Showing results (31-40 of 48) with videos related to
Page
of 5
Sort By:
Cancers
|
March 28, 2024
Multimodal, Technology-Assisted Intervention for the Management of Menopause after Cancer Improves Cancer-Related Quality of Life-Results from the Menopause after Cancer (Mac) Study
Fionán Donohoe, Yvonne O'Meara, Aidin Roberts, et al.
The Oncologist
|
April 25, 2014
Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate
Amir T Fathi, Hossein Sadrzadeh, Amy H Comander, et al.
Irish Journal of Medical Science
|
January 15, 2021
Virtual oncology clinics during the COVID-19 pandemic
David O'Reilly, Hailey Carroll, Mairi Lucas, et al.
Irish Journal of Medical Science
|
May 28, 2024
The impact of expanded access programs for systemic anticancer therapy in an Irish cancer centre
Timothy K Cronin, Cian Ronayne, Niamh O'Donovan, et al.
Cancer Biology & Therapy
|
December 3, 2010
PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells
Michaela J Higgins, Julia A Beaver, Hong Yuen Wong, et al.
The Oncologist
|
May 12, 2021
Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients
Sara M Tolaney, David R Ziehr, Hao Guo, et al.
Journal of the National Cancer Institute
|
March 20, 2018
Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients: CCTG MA.27
Kathrin Strasser-Weippl, Michaela J Higgins, Judith-Anne W Chapman, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 7, 2009
Knockin of mutant PIK3CA activates multiple oncogenic pathways
John P Gustin, Bedri Karakas, Michele B Weiss, et al.
The Oncologist
|
October 30, 2016
Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients
Sara M Tolaney, David R Ziehr, Hao Guo, et al.
Nature Medicine
|
December 9, 2024
Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial
Nadia Harbeck, Eva Ciruelos, Guy Jerusalem, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 48) with videos related to
Sort By:
Page
of 5
Cancers
|
March 28, 2024
Multimodal, Technology-Assisted Intervention for the Management of Menopause after Cancer Improves Cancer-Related Quality of Life-Results from the Menopause after Cancer (Mac) Study
Fionán Donohoe, Yvonne O'Meara, Aidin Roberts, et al.
The Oncologist
|
April 25, 2014
Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate
Amir T Fathi, Hossein Sadrzadeh, Amy H Comander, et al.
Irish Journal of Medical Science
|
January 15, 2021
Virtual oncology clinics during the COVID-19 pandemic
David O'Reilly, Hailey Carroll, Mairi Lucas, et al.
Irish Journal of Medical Science
|
May 28, 2024
The impact of expanded access programs for systemic anticancer therapy in an Irish cancer centre
Timothy K Cronin, Cian Ronayne, Niamh O'Donovan, et al.
Cancer Biology & Therapy
|
December 3, 2010
PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells
Michaela J Higgins, Julia A Beaver, Hong Yuen Wong, et al.
The Oncologist
|
May 12, 2021
Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients
Sara M Tolaney, David R Ziehr, Hao Guo, et al.
Journal of the National Cancer Institute
|
March 20, 2018
Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients: CCTG MA.27
Kathrin Strasser-Weippl, Michaela J Higgins, Judith-Anne W Chapman, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 7, 2009
Knockin of mutant PIK3CA activates multiple oncogenic pathways
John P Gustin, Bedri Karakas, Michele B Weiss, et al.
The Oncologist
|
October 30, 2016
Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients
Sara M Tolaney, David R Ziehr, Hao Guo, et al.
Nature Medicine
|
December 9, 2024
Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial
Nadia Harbeck, Eva Ciruelos, Guy Jerusalem, et al.
Page
of 5